Ed Arce
#7 out of 1697 analysts
WestPark Capital
Automatically Tracked
Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
Gain and growth charts are calculated per selected timeframe:
393.55%
Gain
Monthly
1.96%
Yearly
26.16%
Drawdown
66.11%
$750,339.27
Equity
Holdings
$0
Cash
$750,339.27
Investment
$0
$650,339.27
Profit $0
Realized
$650,339.27
Unrealized
$0
Dividends
$0
$750,339.27
Cash
Deposits
$100,000
Withdrawals
$0
Commissions
$0
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
0%
Profit
$0
Win %
100%
This Week
Compared To Last Week
Gain
11.72%
Profit
$78,706.83
Win %
100%
This Month
Compared to last month
Gain
11.72%
Profit
$78,706.83
Win %
100%
This Year
Compared to last year
Gain
34.07%
Profit
$190,687.2
Win %
100%
TLPH Talphera Inc.
+$271,342.75
ENTA Enanta Pharmaceuticals Inc.
+$177,547.76
ARCT Arcturus Therapeutics Holdings Inc.
+$105,527.55
TVTX Travere Therapeutics Inc.
+$80,340.37
TRVN Trevena, Inc.
+$73,174.14
GALT Galectin Therapeutics Inc.
+$34,436.08
VERA Vera Therapeutics Inc.
+$32,927.21
SGMT Sagimet Biosciences Inc.
+$20,451.19
ALGS Aligos Therapeutics Inc.
+$18,956.45
ATXI Avenue Therapeutics Inc.
+$12,875.45
AKBA Akebia Therapeutics Inc.
+$10,042.06
ARDX Ardelyx Inc.
+$9,067.26
MIRM Mirum Pharmaceuticals Inc.
+$6,259.91
MDGL Madrigal Pharmaceuticals, Inc.
+$5,138.49
UNCY Unicycive Therapeutics Inc.
+$4,627.9
ITRM Iterum Therapeutics plc
+$3,212.4
AUPH Aurinia Pharmaceuticals Inc.
-$91,243.49
GLMD Galmed Pharmaceuticals Ltd.
-$30,684.44
PLRX Pliant Therapeutics Inc.
-$22,886.65
ACXP Acurx Pharmaceuticals, Inc.
-$16,960.19
ABUS Arbutus Biopharma Corporation
-$11,216.94
ZVSA Zyversa Therapeutics Inc.
-$10,055.98
SYBX Synlogic Inc.
-$8,527.2
IVA Inventiva S.A.
-$8,229
RARE Ultragenyx Pharmaceutical Inc.
-$6,398.57
MTVA Metavia Inc.
-$6,198.38
NAMS NewAmsterdam Pharma Co. N.V.
-$3,186.83
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 1561 | Longs Won 741/1561 47% | Profit Factor 2.22 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $8,585.44 |
| Average Win $1,596.57 | Best Trade (Aug 08) $273,375.05 | Sharpe Ratio -44.68 |
| Average Loss -$649.65 | Worst Trade (Jul 25) -$34,152.24 | Z-Score -8.22 (100%) |
| Commissions $0 | Avg. Trade Length 3m 2w 2d | Expectancy $416.62 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | 0.04% | 0.29% | 1.35% | 4.95% | 15.24% | 41.14% |
| Consecutive Losing Trades | 1,155 | 1,039 | 924 | 808 | 693 | 577 | 462 | 346 | 231 | 115 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
